Entrada Reports Q2 2026 Results, Sets Near-Term Clinical Data Catalysts

summarizeSummary

Entrada Therapeutics reported Q2 2026 financial results with $223 million in cash, a $42.8 million net loss, and a roadmap of clinical data catalysts starting in October 2026. The company also announced a new preclinical candidate for Usher syndrome.

check_boxKey Events · Earnings and Guidance · TRDA

• Q2 2026 Financial Results

  Cash, cash equivalents and marketable securities totaled $223.0 million as of June 30, 2026, down from $295.7 million at year-end 2025. Net loss was $42.8 million, or $1.01 per share, compared to $43.1 million a year ago. Collaboration revenue fell to $0.9 million from $2.0 million.

• Cash Runway into Q3 2027

  Management expects current cash to fund operations into the third quarter of 2027, covering multiple upcoming clinical data readouts.

• Near-Term Clinical Catalysts

  ELEVATE-45-201 Cohort 1 data expected in October 2026; ELEVATE-44-201 Cohort 1 open-label data by year-end 2026; ELEVATE-44-201 Cohort 2 data in Q1 2027. Vertex's VX-670 Phase 1/2 data in DM1 expected in H2 2026.

• New Preclinical Candidate ENTR-801

  Entrada announced its first ocular disease candidate, ENTR-801, for Usher syndrome type 2A, with a second ocular candidate to be named in H2 2026.

auto_awesomeAnalysis · TRDA · Life Sciences

Entrada's Q2 update provides a clear financial snapshot and a dense clinical catalyst calendar. The $223 million cash position funds operations into Q3 2027, covering multiple upcoming data readouts that could define the DMD franchise. The stock has been under pressure following mixed Phase 1 data in May, making these near-term milestones critical for investor confidence. The report also introduces a new ocular disease candidate, ENTR-801, expanding the pipeline beyond neuromuscular disease.